Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AiCuris, 4SC Discovery and CRELUX Announce Drug Discovery Collaboration

Published: Tuesday, November 05, 2013
Last Updated: Monday, November 04, 2013
Bookmark and Share
AiCuris will use the high quality integrated drug discovery platform i2c of CRELUX and 4SC Discovery to identify novel therapeutics for infectious diseases.

4SC AG has announced that 4SC Discovery GmbH, CRELUX GmbH and AiCuris GmbH & Co. KG have started a drug discovery collaboration to identify and validate novel small molecule compounds targeting pathogen-specific interactions in infectious diseases.

The collaboration is a further proof for the innovative capacity and the high quality standard of the joint integrated drug discovery platform i2c ('idea-to-candidate'), operated by 4SC Discovery and CRELUX.

Based on i2c, CRELUX and 4SC Discovery will discover and optimize small molecule compounds with the goal to deliver high quality drug candidates for a novel anti-infectious therapeutic approach by AiCuris.

A virtual screening approach using 4SC's proprietary 4Scan® method will be performed to identify various inhibitors to the therapeutic target. Compounds identified as potential inhibitors of the respective target will be verified by using both, established assays at AiCuris and the INTRACT in vitro screening systems at CRELUX.

In the course of the further discovery process, protein structures of verified hits with the target will be solved by i2c to enable rational design and guide the further chemical optimization.

Prof. Helga Rübsamen-Schaeff, CEO of AiCuris comments: 'We are dedicated to fill our early pipeline with highly innovative next generation drugs against infectious diseases with high medical need and which are also active against resistant pathogens. These may be derived from in house research, from licensing or from collaborations.'

Dr. Holger Zimmermann, Managing Director and Chief Scientific Officer at AiCuris adds: 'Based on our good experience in collaborating with 4SC we expect to identify soon first promising hits for further evaluation in our screening cascades. This collaboration is an important contribution to our in house research efforts and supports our goal to discover highly efficacious drugs which help to solve major problems in treating infectious diseases.'

Dr. Michael Schaeffer, Executive Director Strategy and Business of CRELUX GmbH, comments: 'This collaboration is a further proof of the value i2c brings to its clients' drug discovery programmes. With Aicuris, we see a perfect fit of ideas, technologies and know-how and are especially pleased to have gained yet another innovative and reknowned biotech company from Germany as a partner. With this partnership, CRELUX and 4SC Discovery continue to build on their joint strategy to position themselves as premium solution providers to the global pharma and biotech industry covering the complete drug discovery value chain.'

Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer at 4SC AG, comments: 'The selection of i2c as drug discovery platform for AiCuris is an important step in our strategy to become Europe's leading partner for innovative and high quality drug discovery projects. We are particularly delighted, since this new collaboration is built on our long-term trustful relationship and former successful collaborations between AiCuris and 4SC, now targeting next generation high therapeutic needs in antiinfective drug discovery.'

The i2c platform operates on a seamlessly integrated suite of technologies including virtual high throughput screening, molecular modelling, X-ray crystallography, in vitro and cell based screening, medicinal chemistry and pharmacology.

CRELUX and 4SC Discovery are offering integrated drug discovery solutions to clients from the pharmaceutical and biotechnology industry covering the entire value chain of early-stage pharmaceutical research and drug discovery.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
New Diabetes Drug has Unexpected Side Effect
A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to new research.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Cannabis May Be Used to Treat Fractures
TAU researcher finds non-psychotropic compound in marijuana can help heal bone fissures.
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!